QLT Inc.

  • A global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies to treat cancer, eye diseases and immune disorders.
  • Mintz provided QLT with strategic planning in a variety of scenarios from strategic partnership development to customer development.
Chugai Pharmaceutical Co., Ltd.

  • Chugai Pharmaceutical Co. Ltd and its subsidiaries are engaged in drug discovery and development, and market products in Japan and in nations around the world.

  • Mintz worked to form a strategic alliance creating synergy between a medical device and therapeutic developers.

  • Mintz was a member of Chugai’s Business Development Department and supported assessments of biotechnology inlicensing opportunities from North America, Europe and Australia. He also helped facilitate research agreements with leading universities in New England.
Alliance Pharmaceutical Corp.

  • Alliance Pharmaceutical Corp. is a research and development company focused on transforming innovative scientific discoveries into novel therapeutic and diagnostic agents.
  • Mintz researched the market and developed the specification for the product. He also identified potential strategic partners for development and manufacturing. (case study #5)
Advanced Tissue Sciences Inc.

  • ATS developed a dermal graft product for the treatment of burns and diabetic ulcers. 

  • Mintz facilitated discussions between ATS and a major Japanese pharmaceutical company in their due diligence regarding Dermagraft® rights for Asia.

Inex Pharmaceutical Corp.

  • INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.

  • Mintz provided commercial market evaluations of the potential patient populations for treatment of patients with multiply relapsed aggressive non-Hodgkin's Lymphoma using liposomal vincristine (Onco-TCS).

  • Mintz also conducted research relating to potential applications for multiple sclerosis.

Dura Pharmaceuticals

  • Acquired by Elan in 2000, Dura was a specialty pharmaceutical company that marketed and sold prescription products to treat infectious diseases and respiratory conditions.
  • Mintz supported business development efforts at Dura in early 2000 involving European market evaluations for respiratory products.
  • Mintz also managed the divestiture of Dura's Canadian rights to Entex LA, a branded cough/cold medication.
Marine BioProducts, Inc.

  • Marine BioProducts International is a new manufacturer of premium specialty agars for the microbiology, molecular biology life sciences and commercial plant propagation markets.
  • Mintz assisted Marine BioProducts in identifying candidate distributors for its products in Japan.
back to client and experience base      Back to Top
 
Wyeth Lederle Japan, Ltd.

  • Wyeth is a research-based, global pharmaceutical company responsible for the discovery and development of some of today's most innovative medicines. Its Japanese subsidiary owns the approval of Photofrin in Japan.
  • Mintz worked closely with Wyeth Japan's marketing department to create innovative new programs that expanded use of Photofrin among existing users and helped recruit new hospital sites for the treatment program.
Ciba Vision Ophthalmics

  • CIBA Vision's is QLT Inc.'s global partner for marketing and sales of Visudyne, the only approved treatment for slowing the progression of vision loss associated with wet age related macular degeneration (AMD).
  • Mintz worked with the global development team in coordinating market evaluations and early development of Visudyne in Japan and China.
  • Mintz also helped facilitate relationships between Ciba Vision Japan and the Japanese subsidiaries of Coherent and Zeiss.
Hamamatsu Photonics Ltd.
  • Hamamatsu is a leading manufacturer of devices for generation and measurement of infrared, visible, and ultraviolet light. Its products include photodiodes, photomultiplier tubes, scientific light sources, infrared detectors, photoconductive cells, and imaging devices. Hamamatsu developed the first laser approved for use with QLT's cancer therapy Photofrin.
  • Mintz interfaced with Hamamatsu in the promotion of Photofrin in Japan and in discussions to introduce a low-cost laser for expanding the user base of Photofrin.
IHI Co., Ltd.

  • Ishikawajima-Harima Heavy Industry develops a broad range of technologies from tanker ships to aerospace products and medical equipment.  IHI developed a laser for activation of QLT’s Photofrin for sale in Japan.
  • Mintz interfaced with IHI in the promotion of Photofrin in Japan to help drive interest in their laser.  He also held discussions with IHI to introduce a low-cost laser for the Japanese market.
Zeiss Japan

  • One of the world's leading solution providers in the field of ophthalmology. Its product line includes diagnostic and therapy systems for all four main fields of application on the eye.
  • Mintz worked with Zeiss' Japanese subsidiary during the preparation for clinical studies of Visudyne in Japan, facilitating coordination among QLT's partners Ciba Vision KK, Zeiss, and Coherent.
Coherent Japan

  • Coherent is a leading provider of laser equipment for industrial and medical applications. The company developed the first laser approved for use with Photofrin in the U.S.
  • Utilizing semiconductor laser technology, Coherent and Zeiss developed the 690 nm diode lasers used for the activation of Visudyne in the treatment of wet form of age-related macular degeneration.
  • Mintz worked with Coherent’s US sales force in promotion of Photofrin and with Coherent's Japanese subsidiary during the preparation for clinical studies of Visudyne in Japan.
Diomed Inc.

  • Diomed Lasers manufactures semiconductor-based medical lasers and developed the low-cost laser option for activation of Photofrin. Previously available devices required significant capital and maintenance, limiting the potential sites Photofrin could be used.
  • Mintz worked closely with the UK based manufacturer to establish partnerships with interested Japanese distribution candidates in a program designed to expand the Japanese user base.
back to client partner experience      Back to Top
  © 2002 2004 Mintz & Associates